JP2010519915A5 - - Google Patents

Download PDF

Info

Publication number
JP2010519915A5
JP2010519915A5 JP2009552038A JP2009552038A JP2010519915A5 JP 2010519915 A5 JP2010519915 A5 JP 2010519915A5 JP 2009552038 A JP2009552038 A JP 2009552038A JP 2009552038 A JP2009552038 A JP 2009552038A JP 2010519915 A5 JP2010519915 A5 JP 2010519915A5
Authority
JP
Japan
Prior art keywords
nucleoside
analog
integer
inosine
cytosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2009552038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010519915A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2008/000473 external-priority patent/WO2008106803A1/en
Publication of JP2010519915A publication Critical patent/JP2010519915A/ja
Publication of JP2010519915A5 publication Critical patent/JP2010519915A5/ja
Abandoned legal-status Critical Current

Links

JP2009552038A 2007-03-07 2008-03-07 二本鎖のロックされた核酸組成物 Abandoned JP2010519915A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90546107P 2007-03-07 2007-03-07
US95027107P 2007-07-17 2007-07-17
PCT/CA2008/000473 WO2008106803A1 (en) 2007-03-07 2008-03-07 Double-stranded locked nucleic acid compositions

Publications (2)

Publication Number Publication Date
JP2010519915A JP2010519915A (ja) 2010-06-10
JP2010519915A5 true JP2010519915A5 (enExample) 2011-10-27

Family

ID=39737757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009552038A Abandoned JP2010519915A (ja) 2007-03-07 2008-03-07 二本鎖のロックされた核酸組成物

Country Status (10)

Country Link
US (1) US20090041809A1 (enExample)
EP (1) EP2125853A1 (enExample)
JP (1) JP2010519915A (enExample)
KR (1) KR20100051041A (enExample)
CN (1) CN101687900A (enExample)
AU (1) AU2008222523A1 (enExample)
BR (1) BRPI0808442A2 (enExample)
CA (1) CA2680060A1 (enExample)
MX (1) MX2009009530A (enExample)
WO (1) WO2008106803A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228540D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compositions
AU2009255947B2 (en) 2008-06-06 2014-12-18 Aurora Algae, Inc. Vcp-based vectors for algal cell transformation
JP5775451B2 (ja) 2008-06-19 2015-09-09 バリエーション バイオテクノロジーズ インコーポレイティド インフルエンザを処置するための組成物および方法
WO2010107503A1 (en) 2009-03-19 2010-09-23 Millipore Corporation Removal of microorganisms from fluid samples using nanofiber filtration media
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US9029137B2 (en) 2009-06-08 2015-05-12 Aurora Algae, Inc. ACP promoter
US8865468B2 (en) 2009-10-19 2014-10-21 Aurora Algae, Inc. Homologous recombination in an algal nuclear genome
US8809046B2 (en) 2011-04-28 2014-08-19 Aurora Algae, Inc. Algal elongases
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
MX2012000372A (es) 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
WO2011011463A2 (en) * 2009-07-20 2011-01-27 Aurora Biofuels, Inc. Manipulation of an alternative respiratory pathway in photo-autotrophs
EP2482825B1 (en) 2009-10-02 2016-11-23 The Trustees of Columbia University in the City of New York Piscine reovirus diagnostic compositions
US8846388B2 (en) * 2009-10-16 2014-09-30 Zoetis Llc Infectious clones of torque teno virus
US8492358B2 (en) * 2010-06-25 2013-07-23 Idera Pharmaceuticals, Inc. Agonists of toll-like receptor 3 and methods of their use
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
SG10201600617PA (en) 2010-08-10 2016-11-29 Emd Millipore Corp Method for retrovirus removal
WO2012087964A1 (en) * 2010-12-23 2012-06-28 Codexis, Inc. Gene disruptants producing fatty acyl-coa derivatives
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US8722359B2 (en) 2011-01-21 2014-05-13 Aurora Algae, Inc. Genes for enhanced lipid metabolism for accumulation of lipids
WO2012135679A2 (en) 2011-04-01 2012-10-04 Emd Millipore Corporation Nanofiber containing composite structures
AU2012249377A1 (en) 2011-04-28 2013-11-14 Aurora Algae, Inc. Algal desaturases
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP4008354A1 (en) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
US9157101B2 (en) * 2012-12-21 2015-10-13 Algenol Biotech LLC Cyanobacterium sp. for production of compounds
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
EP3835419A1 (en) 2013-12-12 2021-06-16 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
US12059644B2 (en) 2014-06-26 2024-08-13 Emd Millipore Corporation Filter structure with enhanced dirt holding capacity
WO2016061131A1 (en) 2014-10-14 2016-04-21 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
AU2015371292A1 (en) 2014-12-23 2017-07-20 Algenol Biotech LLC Methods for increasing the stability of production of compounds in microbial host cells
KR102206963B1 (ko) 2015-04-17 2021-01-25 이엠디 밀리포어 코포레이션 접선방향 유동 여과 모드에서 작동되는 나노섬유 한외여과막을 사용하여 샘플에서 목적하는 생물학적 물질을 정제하는 방법
US10392607B2 (en) 2015-06-03 2019-08-27 The Regents Of The University Of California Cas9 variants and methods of use thereof
US10138489B2 (en) 2016-10-20 2018-11-27 Algenol Biotech LLC Cyanobacterial strains capable of utilizing phosphite
WO2019016605A1 (en) 2017-07-21 2019-01-24 Merck Millipore Ltd MEMBRANES OF NONWOVEN FIBERS
WO2019066571A2 (ko) 2017-09-28 2019-04-04 연세대학교 산학협력단 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도
WO2019211492A1 (en) * 2018-05-04 2019-11-07 Tollys Tlr3 ligands that activate both epithelial and myeloid cells
EP3841205A4 (en) 2018-08-22 2022-08-17 The Regents of The University of California VARIANT TYPE V CRISPR/CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
WO2020097445A1 (en) 2018-11-09 2020-05-14 Inari Agriculture, Inc. Rna-guided nucleases and dna binding proteins
EP4219700A1 (en) 2019-03-07 2023-08-02 The Regents of the University of California Crispr-cas effector polypeptides and methods of use thereof
KR102256001B1 (ko) * 2019-07-02 2021-05-26 주식회사 엔에이백신연구소 신규한 리보핵산 및 이를 기반으로 하는 약제학적 조성물
AU2020299074B2 (en) 2019-07-02 2024-02-22 Na Vaccine Institute Novel ribonucleic acid and pharmaceutical composition based on the same
US20230302158A1 (en) * 2020-08-14 2023-09-28 Allen Institute Artificial expression constructs for modulating gene expression in striatal neurons
TW202308629A (zh) 2021-04-28 2023-03-01 法商Ｅｎｙｏ製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692899A (en) * 1969-12-17 1972-09-19 Us Health Education & Welfare Inhibition of transplanted tumor growth by polyinosinic-polycytidylic acid in mice
US4024241A (en) * 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US3952097A (en) * 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4349538A (en) * 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
AU713040B2 (en) * 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
JP3756313B2 (ja) * 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CA2203843C (en) * 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6083482A (en) * 1999-05-11 2000-07-04 Icn Pharmaceuticals, Inc. Conformationally locked nucleosides and oligonucleotides
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
AU2003203079B9 (en) * 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
EP1778186B1 (en) * 2002-07-03 2011-11-30 Oncovir, Inc. Method for preparation of poly-iclc and uses thereof
GB0228540D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compositions
WO2005004794A2 (en) * 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7834064B2 (en) * 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
WO2007050990A2 (en) * 2005-10-27 2007-05-03 Rosetta Inpharmatics Llc Nucleic acid amplification using non-random primers
EP2202239A1 (en) * 2005-11-01 2010-06-30 Alnylam Pharmaceuticals Inc. RNAI inhibition of influenza virus replication

Similar Documents

Publication Publication Date Title
AU2021206780C1 (en) Compositions and methods for synthesizing 5'-Capped RNAs
JP6640290B2 (ja) 核酸の非特異的標的の捕捉方法
CN102124020B (zh) 自回避分子识别系统用于dna扩增
AU2008260277B2 (en) N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
JP2010525813A5 (enExample)
RU2014130600A (ru) Антисмысловые нуклеиновые кислоты
NZ598943A (en) Hbv antisense inhibitors
JP2012502657A5 (enExample)
JP2011502502A5 (enExample)
WO2008106803A1 (en) Double-stranded locked nucleic acid compositions
JP2019529406A5 (enExample)
CN101978071A (zh) 用于杂交核酸的方法
JP2021505129A5 (enExample)
ES2300375T3 (es) Composiciones y metodos para la deteccion del virus de la inmunodeficiencia humana 2 (hiv-2).
JP2019534025A5 (enExample)
JP2019534025A (ja) 治療用オリゴヌクレオチドの捕捉および検出
WO2010040033A4 (en) Methods and compositions for modulating an immune response with immunogenic oligonucleotides
JP5646455B2 (ja) チクングニヤウイルスを検出するための方法
WO2010090969A4 (en) Tetrahydropyran nucleic acid analogs
JP2013513359A5 (enExample)
De Bouvere et al. Hexitol nucleic acids (HNA): synthesis and properties
ES2383947T3 (es) Composiciones, métodos y equipos para la detección de ácidos nucleicos del vih-1 y vih-2
EP4342999B1 (en) Compositions, kits and methods for isolating target polynucleotides
HK40084740B (en) Compositions, kits and methods for isolating target polynucleotides
HK40084740A (en) Compositions, kits and methods for isolating target polynucleotides